Lemborexant and Melatonin Combination for Insomnia Treatment

Introduction to Melatonin's Limited Role

• The American Academy of Sleep Medicine recommends against using melatonin as a treatment for sleep onset or sleep maintenance insomnia in adults, due to weak evidence showing only a 9-minute reduction in sleep latency compared to placebo 1, 2, 3
• Melatonin has minimal clinical benefit in chronic insomnia, with only small improvements in quality of sleep 4, 5

Safety and Efficacy Considerations

• The American Academy of Sleep Medicine notes that combination therapy data is generally lacking for insomnia medications, including lemborexant and melatonin 6, 7
• Melatonin is generally well-tolerated with minimal adverse effects reported in clinical trials 4, 5

Clinical Recommendations

• If a patient is already taking melatonin and requires additional insomnia treatment, consider discontinuing melatonin given its lack of evidence-based benefit for chronic insomnia 1, 2, 3
• Cognitive-behavioral therapy for insomnia (CBT-I) should be offered as first-line treatment when available 11
• All pharmacologic insomnia treatments, including lemborexant, carry weak strength of evidence by GRADE methodology and should be used short-term when possible 11

Specific Considerations for Melatonin

• Melatonin may have a role in circadian rhythm disorders, such as delayed sleep phase or jet lag, but not primary insomnia 8, 9, 10